VIVO Meridian Bioscience Inc.

Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

Meridian’s New Master Mix for LAMP Assays Offers a Practical Solution for POC Molecular Detection of RNA viruses

CINCINNATI, June 16, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ RT-LAMP Mix, specifically designed for accelerating the development of ambient temperature stable reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assays. The Lyo-Ready™ RT-LAMP Mix is formulated for rapid, robust, and sensitive detection of RNA viruses.

RT-LAMP technology is perfectly suited for point-of-care or portable testing because assays are performed at one single temperature, which reduces the cost and complexity of the device without the requirement of a thermocycler. RT-LAMP has been successfully used in the diagnosis of infectious diseases caused by RNA viruses, such as influenza, hepatitis C, West Nile fever, Dengue virus and Ebola virus. The accuracy and relatively simple equipment requirement makes RT-LAMP the perfect technology for use as a practical solution for point-of-care detection of viruses, particularly in non-standard institutions such as airports, rural hospitals or in the home. Applications for this technology go beyond human diagnostics expanding to veterinary, environmental, AgBio, and food testing.

However, in order to have this wide reach, RT-LAMP diagnostic developers need to eliminate the need for cold storage of the assay.   To facilitate development of tests that can be stored at ambient temperature, Meridian has designed the new Lyo-Ready™ RT-LAMP 1-Step Mix as a glycerol-free, and uniquely high 4x concentration format mix, containing pre-optimized lyo-excipients. Its unique formulation expedites the assay optimization, reducing development time of room temperature stable RT-LAMP assays with superior amplification sensitivity and specificity.

Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development – Life Science, commented, “Our new Lyo-Ready RT-LAMP mix contains all enzymes required for RNA detection with reverse transcriptase and Bst Polymerase in a lyophilization compatible format. With the pressing needs of COVID-19 testing, lyophilization opens the door to a faster and near patient alternative to the diagnosis. We are delighted to announce the release of our new Lyo-Ready™ LAMP 1-Step Mix, which outperforms the competition with market leading sensitivity and specificity while also enabling point-of-care with ambient temperature storage capability.”

Meridian is committed to providing innovative solutions to diagnostic manufacturers that simplify and accelerate the development of superior diagnostic assays. For more information about partnering with Meridian Bioscience, please visit or contact Dr. Chang-Pi-Hin at .        

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is .

Contact:

Charlie Wood

Vice President – Investor Relations

Meridian Bioscience, Inc.

Phone: +1 513.271.3700

Email:



EN
16/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Meridian Bioscience Inc.

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences...

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum. Saliva is a complex fluid containing various enzy...

 PRESS RELEASE

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submi...

 PRESS RELEASE

Meridian Closes Acquisition of BreathTek® Business

Meridian Closes Acquisition of BreathTek® Business CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021. About Meridian Bioscience, Inc.Meridian is ...

 PRESS RELEASE

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H....

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationshi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch